RPR/Fisons tender offer succeeds; RPR sees "irreversible" decline in Intal franchise.
FISONS TILADE 1994 SALES "ONLY [pound]41 MIL.," or $64 mil., "after eight years on the market," Rhone-Poulenc Rorer declares in its final offer document for its hostile takeover of Fisons. Tilade (nedocromil sodium) "was forecast in 1991 to be a [pound]200 mil. sales product," RPR wrote to Fisons shareholders. RPR contends that Fisons' Intal/Tilade mast-cell stabilizer franchise "is falling substantially behind the growth in the asthma market."
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth